anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The present invention relates to an herbal cosmetic composition for protecting the skin and scalp and a method for producing the same, wherein the herbal cosmetic composition contains extract of saxifrage, coptis, houttuynia, ginseng, Peony roots, Paeonia suffruticosa, yeast extract, and Pleuropterus multiflorus. The herbal cosmetic composition is produced i) by sequentially mixing saxifrage, coptis, houttuynia, ginseng, Peony roots, Paeonia suffruticosa, yeast extract, and Pleuropterus multiflorus to be extracted through ethanol, heating the ethanol extract, cooling generated steam to remove a solvent and obtain a liquid concentrate or ii) by sequentially performing ethanol extraction respectively on saxifrage, coptis, houttuynia, ginseng, Peony roots, Paeonia suffruticosa, yeast extract, and Pleuropterus multiflorus, heating each ethanol extract, and cooling generate steam to remove a solvent and respectively obtain liquid concentrates to be mixed. Several sorts of vitamins and vitamin precursors which are helpful for human body metabolism are further included so that a hair growing function of the herbal cosmetic composition can be reinforced. The herbal cosmetic composition according to the present invention controls in vivo 5-reducing enzymes so that DHT is not generated during the metabolic process of male hormones. As for the functional process of human body epithelial tissues, cell reproduction helps the metabolism of hair so that the herbal cosmetic composition, as a hair growth composition, can be used in treating male pattern alopecia. The herbal cosmetic composition is effective in preventing hair loss, and it is suitable to add the same in a cosmetic product for protecting skin and scalp.
The invention relates to medicinal means on the basis of a peptide pharmaceutical composition for treatment of  Helicobacter pylori -induced gastroduodenal diseases. The technical result of the invention consists in the peptide glutamyl-aspartyl-glycine with formula: H-Glu-Asp-Gly-OH revealing a specific activity manifested in an inhibiting effect on mitochondrial mechanisms of  Helicobacter pylori -induced apoptosis in gastric epitheliocytes, which hinders the  Helicobacter pylori  influence on the cells and reduced apoptosis induction. Claimed is a pharmaceutical composition having a specific activity manifested in an inhibiting effect on mitochondrial mechanisms of  Helicobacter pylori -induced apoptosis in gastric epitheliocytes, characterized in that it comprises an amount, effective on  Helicobacter pylori , of the peptide with formula H-Glu-Asp-Gly-OH as the active substance, and a pharmaceutically acceptable carrier, as well as a use of the pharmaceutical composition for producing a means for treatment of  Helicobacter pylori -induced gastroduodenal diseases, comprising an amount, effective on  Helicobacter pylori , of the peptide with formula H-Glu-Asp-Gly-OH as the active substance, and a pharmaceutically acceptable carrier. According to the invention, the means comprised the active substance in the amount of 1 μg/kg to 10 μg/kg. According to the invention, the means exists in the form suitable for oral or parenteral administration. Claimed is a method for treatment of  Helicobacter pylori -induced gastroduodenal diseases by inhibiting  Helicobacter pylori -induced apoptosis in gastric epitheliocytes comprising administering to a subject in need thereof a means comprising an amount, effective on  Helicobacter pylori , of the peptide with formula H-Glu-Asp- Gly-OH in the dose of 1 μg to 10 μg per 1 kg of body weight orally, daily, 3 times a day for 10-20 days, or parenterally, daily, once a day, for 10 days. According to the invention, the administration is performed orally or parenterally.
Liquid suspension of radiprodil, at concentrations 0.25 mg/mL or 2.50 mg/mL for 1% and 10% formulation respectively. It will be administered twice a day (bid) either orally or via gastric or nasogastric tube, slowly up-titrated to the highest tolerated dose.
Lansoprazole (Takepron), tablets, orally, once daily for up to 8 weeks. Reflux esophagitis: the usual adult dosage is 30 mg of lansoprazole. For maintenance therapy of repeatedly recurring/relapsing reflux esophagitis, the dosage is 15 mg of lansoprazole administered orally once daily. If insufficient efficacy is observed, the dosage may be increased to 30 mg administered orally once daily. Nonerosive gastroesophageal reflux disease: the usual adult dosage is 15 mg of lansoprazole administered orally once daily for up to 4 weeks.
Teratogenic effects: Buprenorphine was not teratogenic in rats or rabbits after I.M. or S.C. doses up to 5 mg/kg/day (approximately 48 and 95 times the recommended human daily dose of 1.2 mg on a mg/m2 basis), I.V. doses up to 0.8 mg/kg/day (approximately 8 times and 15 times the recommended human daily dose of 1.2 mg on a mg/m2 basis), or oral doses up to 160 mg/kg/day in rats (approximately 1525 times the recommended human daily dose of 1.2 mg on a mg/m2 basis) and 25 mg/kg/day in rabbits (approximately 475 times the recommended human daily dose of 1.2 mg on a mg/m2 basis). Significant increases in skeletal abnormalities (e.g. extra thoracic vertebra or thoraco-lumbar ribs) were noted in rats after S.C. administration of 1 mg/kg/day and up (approximately 9.5 times the recommended human daily dose of 1.2 mg on a mg/m2 basis) and in rabbits after I.M. administration of 5 mg/kg/day (approximately 95 times the recommended human daily dose of 1.2 mg on a mg/m2 basis), but these increases were not statistically significant. Increases in skeletal abnormalities after oral administration were not observed in rats, and increases in rabbits (1-25 mg/kg/day) were not statistically significant.

There are no adequate and well-controlled studies in pregnant women. Buprenorphine hydrochloride should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
OBJECTIVES: Addressing the challenges of ambulatory surgery involves balancing effective pain relief with minimizing the side effects of pain medication. Due to the heightened risk of opioid abuse, Helsinki University Hospital (Finland) has had a stringent oxycodone prescription policy. This policy prompts an exploration into whether ambulatory surgery patients experience severe post-surgical pain and whether an increase in prescribed opioids would cause elevation in adverse effects.
METHODS: This prospective cohort study, with a 1-week follow-up, included 111 adult ambulatory surgery patients (orthopaedics, urology). The patients documented their pain levels within the first postoperative week (using a numerical rating scale [NRS] of 0-10) and pain medication intake up to two days postoperatively. Furthermore, they completed a questionnaire assessing their satisfaction with pain relief, medication-related adverse effects, and adherence to instructions. Medication intake was cross-referenced with the provided instructions and prescriptions.
RESULTS: A notable 56% of patients reported experiencing intense pain (NRS ≥5) within a week following surgery. Of these, 52% received a single dose of slow-release oxycodone (5-20 mg) at discharge for use on the night of surgery. Predominantly prescribed pain medications included a combination of paracetamol and codeine (64%) or ibuprofen (62%). Satisfaction rates were high, with 87% expressing satisfaction with pain medication given at hospital discharge and 90% expressing contentment with the prescribed medication. The most common adverse effects were tiredness/grogginess (45%), sleep disturbances (38%), nausea (37%), and constipation (27%). Also, 24% of patients self-reported deviations from medication instructions. A comparison of self-reported and instructed medications revealed that 14% exceeded prescribed dosages, and 28% opted for preparations different from those prescribed. Notably, patients who self-reported deviations from instructions differed from those objectively deviating from instructions.
CONCLUSIONS: Although 56% of patients had intense pain, the majority expressed satisfaction with the provided pain relief. Instances of non-adherence to medication instructions were prevalent, often going unnoticed by the patients themselves.
This group will serve as the experimental arm. They will undergo twice daily pulse lavage of their wounds for 4 days. In between the lavage treatments, their wounds will be dressed with moist gauze.
Cold pack (15 minutes); pulsed ultrasound therapy (1 watt/cm², 3 MHz, 1:2 pulsed mode; 3 minutes); transcutaneous electrical nerve stimulation (60-120 Hz; 20 minutes) and exercises (20 minutes). The exercises included stretching, strengthening and posture exercises.
PURPOSE: A composition containing a water extract of Tremella foliacea Fr. is provided to suppress digestion and absorption of fat in the body, and to prevent or treat obesity. CONSTITUTION: A composition for preventing or treating obesity contains a water extract of Tremella foliacea Fr. as an active ingredient. A pharmaceutical product for preventing or treating obesity contains the water extract as an active ingredient. A health functional food for preventing or treating obesity contains the water extract as an active ingredient. A method for preventing or treating obesity comprises a step of administering the water extract to animals exclusive of human. The water extract suppresses activity of pancreatic lipase. The water extract is prepared from Tremella foliacea Fr. with water at 20-60 deg. C for 12-36 hours. [Reference numerals] (AA) TGL activity inhibition(%); (BB) Water extract; (CC) (Comparative example) Ethanol extract
The investigators will conduct this R34 project at the Rhode Island Hospital ED, the primary site for many of the research team's previous HIV (Human Immunodeficiency Virus) and HCV (Hepatitis C Virus) testing studies. Dr. Beaudoin (PI) is an attending physician at the Rhode Island Hospital ED. Our multi-disciplinary team consists of researchers with extensive experience in HIV and HCV testing research, intervention development and testing, and qualitative, quantitative and cost-effectiveness research.

First, the investigators will examine our primary objective in this R34 pilot RCT( Randomized Controlled Trial) of comparing the persuasive health communication intervention to the video. Second, the investigators can compare WITHIN study arms (HIV/HCV counselor arm, ED medical staff arm) and ACROSS these study arms uptake of HIV/HCV testing among participants. Second, the design permits the investigators to obtain initial efficacy data of the persuasive health communication intervention when used by HIV/HCV counselors vs. ED medical staff (ACROSS study arms), as well as compared to the video (WITHIN study arms). Third, the design replicates our subsequent R01 RCT when the investigators compare HIV/HCV screening uptake when conducted solely by HIV/HCV counselors vs. ED medical staff.
PROBLEM TO BE SOLVED: To provide a connecting construction having excellent workability when connecting an end portion to side face portion of structural members of a building and also offering connections between structural members of the building at arbitrary intervals. SOLUTION: An end portion 14 of a sub-component 12 which is a structural member 10 having a cross section almost square and a side face portion 13 of a main structural member 11 are connected together with a connecting device 20. The structural member 10 has gutters 17 and 17 symmetrically about a center line L in a longitudinal direction along each of side faces 15 and 16. The first connecting portion 21 of the connecting device 20 is equipped with a pair of opposite portions 22 and 23 and a middle portion 24 and is fitted to a side face portion 13 of the main structural member 11 straddling three surfaces 15, 16 and 16 of the main structural member 11. The second connecting portion 29 of the connecting device 20 is fitted to the end portion 14 of the structural member.  Projections 25 and 25 respectively fitted to gutters 17 and 17 are provided at the opposite portions 22 and 23 of the first connecting portion 21.
Group A sustained natural apophyseal glides will be provided to wrestlers in the sitting position. SNAG technique applied on the dorsal side of the neck. The treatment will be given for 6 weeks, 2 sessions per week.
Drug: Azelastine Hydrochloride 0.137 MG/ACTUAT Nasal Spray, 1 spray per nostril twice daily for 14 days, with 3 to 7 days of lead-in period. At a certain point during the study, patients will receive Placebo.
Hypoxia can trigger a sequence of breathing-related behaviors, from augmentation to apneusis to apnea and gasping. Gasping is an autoresuscitative behavior that, via large tidal volumes and altered intrathoracic pressure, can enhance coronary perfusion, carotid blood flow, and sympathetic activity, and thereby coordinate cardiac and respiratory functions. We tested the hypotheses that hypoxia-evoked gasps are amplified through a disinhibitory microcircuit within the inspiratory neuron chain and that this drive is distributed via an efference copy mechanism. This generates coordinated gasplike discharges concurrently in other circuits of the raphe-pontomedullary respiratory network. Data were obtained from six decerebrate, vagotomized, neuromuscularly blocked, and artificially ventilated adult cats. Arterial blood pressure, phrenic nerve activity, end-tidal CO2, and other parameters were monitored. Hypoxia was produced by ventilation with a gas mixture of 5% O2 in nitrogen. Neuron spike trains were recorded at multiple pontomedullary sites simultaneously and evaluated for firing rate modulations and short-timescale correlations indicative of functional connectivity. Experimental perturbations evoked reconfiguration of raphe-pontomedullary circuits during initial augmentation, apneusis and augmented bursts, apnea, and gasping. Functional connectivity, altered firing rates, efference copy of gasp drive, and coordinated incremental blood pressure increases support a distributed brain stem network model for amplification and broadcasting of inspiratory drive during autoresuscitative gasping. Gasping begins with a reduction in inhibition by expiratory neurons and an initial loss of inspiratory drive during hypoxic apnea and culminates in autoresuscitative efforts. NEW & NOTEWORTHY Severe hypoxia evokes a sequence of breathing-related behaviors culminating in gasping. We report firing rate modulations and short-timescale correlations in spike trains recorded simultaneously in the raphe-pontomedullary respiratory network during hypoxia. Our findings support a disinhibitory microcircuit and a distributed efference copy mechanism for amplification of gasping. Coordinated increments in blood pressure lead to a model for autoresuscitative bootstrapping of peripheral chemoreceptor reflexes, breathing, and sympathetic activity, complementing and extending prior work.
Catheter ablation for pulmonary vein isolation (PVI) is the most effective treatment method for atrial fibrillation (AF). For a long time, radiofrequency energy (RFA) was dominantly used for ablation, which leads to tissue heating and thus thermal damage. The methodology of pulsed-field ablation, or irreversible electroporation, has been completely newly developed. This form of energy does not lead to thermal tissue damage (as is the case with radiofrequency energy), but with the help of high-intensity nanopulses of electrical energy, the ion channels of cardiomyocytes are permanently opened, the concentration gradient of ions is canceled and thus their irreversible destruction. In addition to the electrical isolation of the pulmonary vein, standard radiofrequency isolation of the pulmonary veins leads to the ablation of collateral ganglion plexuses and thus to the influence of the autonomic nervous system. This is very positive, an imbalance between sympathetic and parasympathetic innervating the left atrium is considered a risk factor for AF induction, and its damage with standard RFA is considered part of the RFA ablation effect. Available studies suggest that PFA probably induces significantly weaker and less permanent suppression of cardiac autonomic regulation compared to RF energy used for PVI.

Measuring heart rate variability is a simple non-invasive method. A regular ECG Holter recorder can be used for the measurement. Patients will be fitted with a 24-hour Holter ECG on admission to determine the original heart rate variability. Catheter ablation will take place the next day. Patients will be treated using one of two methods of pulmonary vein isolation - RFA or PFA. One month after the catheterization procedure, a 24-hour Holter ECG will be used again to detect changes in HRV compared to preoperative values.
The present disclosure discloses trehalose for use in treatment of neurological disorders, wherein the trehalose is for a single daily administration with the daily dose between about 0.25 to about 12.5 g/kg/day. The daily dose may be about 2.67 g/kg/day. A method for treating a neurological disorders is disclosed which involves administering trehalose to a subject as a single daily administration with a daily dose between about 0.25 to about 12.5 g/kg/day and in an embodiment of this method the daily dose is about 2.67 g/kg/day. Also disclosed herein is the use of trehalose in the manufacture of a medicament for treatment of neurological disorders, wherein the trehalose is formulated as a single daily dose with the trehalose present in the medicament in an amount of between about 0.25 to about 12.5 g/kg/day. In an embodiment the daily dose is about 2.67 g/kg/day. The present disclosure provides a pharmaceutical composition for treating neurological disorders, comprising a daily dose of trehalose, and a pharmaceutically acceptable carrier wherein the daily dose of the trehalose is between about 0.25 to about 12.5 g/kg. The trehalose may be formulated as part of a foodstuff.
Eligible participants who consent to the study will be asked to complete questionnaires about socio-demographic characteristics, literacy, and technology comfort. Subsequently, participants will be asked to complete the CHAMP tool at home or in the clinic before the participants' medical appointment with the clinician. Next, participants will see the clinician for the consultation. Approximately one week after the consultation, participants will be asked to complete 3 questionnaires about the participants' experience and satisfaction with the CHAMP tool.
Term pregnant women \> 37 weeks gestation with a normal pregnancy. One blood sample after spontaneous rupture of membranes, but without labor contractions.
Medicinal or cosmetic compsns. (I) for use against lice, comprise a mixt. of insecticides and antioxidants at 0.5-10 wt.%. The compsn. is obtd. and stabilised by dilution and suspension of the active ingredients in an aq. or hydro-organic base. It is in the form of lotions, shampoos, milks, gels, collars or hair accessories. For use against fleas it contains essential oils at 2-10 wt.% associated with antioxidants at 0.1-5 wt.%. USE/ADVANTAGE - (I) are used to treat infestations of lice(pediculus capitis) and their nits and related parasites (p. humans and p. pubis) in man and animals, and in animals, partic. dogs and cats, to reduce or destroy fleas and ticks. (I) can be used in a delayed release form in animal collars, head-bands and the side-pieces of spectacles. Compsns. of prior art pose problems of insecticide resistance, local intolerance, bad odour and in the destruction of nits, limited efficacy. The antioxidants in (I) interfere with sclerotization and hence envelope formation in the nit, glue to the hair and exoskeleton formation. Thus the sensitivity to insecticides is increased possibly allowing reduced dosages.
Patients randomized to this study arm includes the CardiaMend which will be used according to the instructions for use. It will be patted dry to facilitate implantation. Pieces will be cut to cover the right and left atria. The remaining piece will be contoured to close the anterior pericardial space. Four ampules of amiodarone (150mg/3ml; 12cc total volume) will be drawn into a syringe. 2cc will be dripped over the right atrium and a small CardiaMend patch placed to cover this area. Another 2cc will be used over the left atrium and covered with the CardiaMend. The anterior pericardial space will be closed without putting pressure on the underlying structures using the CardiaMend attached to the native pericardium utilizing running 4-0 monofilament suture.
<P>PROBLEM TO BE SOLVED: To provide a gelatine-like protein as a cancer metastasis inhibitor.  <P>SOLUTION: An RGD (arginine-glycine-aspartic acid)-enriched gelatine has an even distribution of RGD sequences as compared with natural gelatine with a minimum level of the RGD sequences, specifically has at least 0.4 ratio of the RGD sequences to the total number of amino acids and each stretch of 350 amino acids contains at least one RGD motif when the RGD-enriched gelatine contains ≥350 amino acids. The RGD-enriched gelatine is preferably prepared by a recombinant technique and has a sequence derived from a human gelatine or collagen amino acid sequence. The RGD-enriched gelatine provides the good cancer metastasis inhibitor. Furthermore, the RGD-enriched gelatine can be used within a wide range of medical applications.  <P>COPYRIGHT: (C)2008,JPO&INPIT